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Endoscopy showed resolution of GvHD in the colon and duode-
num. Video visualization was performed to evaluate the distal small
bowel using the M2A endoscopic capsule by Given Imaging. The
duodenum and colonic mucosa appeared normal, but the jejunum
and ileum had severe diffuse bleeding ulcerations. The video cap-
sule is 11mm 26mm, weighs less than 4 grams, has a ﬁeld of view
of 140 degrees, and can detect lesions less than 0.1mm. The camera
takes pictures for 8 hours and generates approximately 57,000
images at 2 frames per second. Contraindications include suspected
obstruction or stricture, presence of a cardiac pacemaker, or a
swallowing disorder. Video visualization gives valuable informa-
tion on the status of the distal small bowel that cannot be obtained
by ﬁberoptic endoscopy and may aid in evaluation of GvHD
following allogeneic BMT.
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SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR: ENBREL (ETANER-
CEPT) FOR THE TREATMENT OF IDIOPATHIC PNEUMONIA SYNDROME
FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION
Yanik, G.A.1, Uberti, J.P.1, Ferrara, J.L.M.1, Levine, J.E.1, Hutchin-
son, R.J.1, Ho, V.T.2, Cooke, K.R.1 1. University of Michigan Medical
Center, Ann Arbor, MI; 2. Dana-Farber Cancer Institute, Boston, MA
Non-infectious lung injury is as a frequent and severe complica-
tion of allogeneic bone marrow transplantation (BMT). In the
acute setting, a diffuse non-infectious process termed Idiopathic
Pneumonia Syndrome (IPS) may occur. Despite advances in sup-
portive care and the use of high dose steroids, mortality from IPS
remains unacceptably high ( 70%). Etanercept is a soluble tumor
necrosis factor (TNF) receptor, consisting of two soluble p75 TNF
receptors fused to the Fc portion of a human IgG1. A trial exam-
ining etanercept in the treatment of IPS following allogeneic
transplant has now been undertaken. Fourteen patients (median 18
yrs, range 1-60 yrs), each meeting the diagnostic criteria for IPS
were treated. Broncho-alveolar lavage (BAL) specimen were ob-
tained pre and post therapy, undergoing analysis for both infec-
tious pathogens (viral, bacterial, fungal, PCP, AFB) and for inﬂam-
matory cytokine markers (TNF, TNFR1, sCD-14, LBP, and
MCP-1). Patients in whom the pre-therapy BAL was positive for a
potential pathogen (by speciﬁc stain or culture) were ineligible for
therapy. Etanercept was administered subcutaneously at a dose of
0.4 mg/kg (maximum dose 25 mg) twice weekly, for a maximum of
8 doses. All patients required supplemental oxygen at therapy
onset, with seven patients requiring mechanical ventilation. Etan-
ercept therapy was initiated a median of 17 days (range 11-87 days)
post transplant. Results: Therapy was well tolerated, with no
infusion related reactions. Eight of 14 patients had a complete
response, deﬁned as the ability to withdraw completely from sup-
plemental oxygen support. In those responding, the median time to
complete response was 7 days (range 3-18 days), and the median
time to normalization of radiographic ﬁndings was 6 days (range
2-10 days). Two other patients had a signiﬁcant reduction in their
FiO2 requirement during therapy. Three patients died while on
therapy, from progressive organ dysfunction. Post therapy BAL
ﬂuid analysis noted a signiﬁcant reductions in all inﬂammatory
cytokines tested, including TNFa, TNFR1, sCD14, LBP and
MCP-1 (Table below). Conclusion: Etanercept therapy was well
tolerated, with minimal toxicity and favorable response in patients
with IPS post allogeneic transplant. The clinical and biochemical
responses seen with therapy support a mechanistic role for TNFa
in the pathogenesis of this disorder. Further trials, investigating the
responsiveness of IPS to etanercept therapy are warranted.
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NEUROLEPTIC MALIGNANT SYNDROME FOLLOWING STEM CELL
TRANSPLANTATION
Craig, M., Ericson, S., Schunn, G., Beall, C.L. Mary Babb Randolph
Cancer Center, West Virginia University, Morgantown, WV
Neuroleptic malignant syndrome (NMS) is a rare disorder pre-
senting with hyperthermia, muscle rigidity, autonomic instability,
and altered consciousness. Although NMS is usually associated
with antipsychotic medications, it has also been described in pa-
tients receiving antiemetics. The estimated incidence in susceptible
populations is about 0.2%, with an associated mortality rate 10-
20%. Three cases of NMS following bone marrow or peripheral
blood stem call transplantation have been described in the medical
literature. We present an additional patient for review. A 51 year-
old female underwent autologous peripheral blood stem cell trans-
plantation for IgA kappa multiple myeloma with high dose mel-
phalan. She achieved engraftment on day 14. Her post-
transplantation course was complicated by persistent nausea and
vomiting requiring treatment with prochlorperazine or prometh-
azine. On day 20, she developed fever of 39.4°C, labile blood
pressure, elevated pulse, and delirium. Antimicrobials were begun
for presumed sepsis. Cultures were negative. By day 21, her
temperature had climbed to 40.9°C, delirium continued, and mus-
cle rigidity developed, with an elevation in CK. She had a gener-
alized tonic-clonic seizure. NMS was diagnosed based on her
clinical scenario and all antiemetics were discontinued. Dantrolene
sodium was initiated IV. Response occurred with resolution of
temperature, decreased muscle rigidity, and improved mental sta-
tus within 24 hours. Previous reports of NMS following transplan-
tation include 2 cases diagnosed 9 and 11 days following autolo-
gous transplantation for liposarcoma and breast cancer (Garrido
SM, et al. Bone Marrow Transplantation 1998;21:427-8). Another
was seen 6 days after allogeneic transplant for AML (Onose M, et
al. Bone Marrow Transplantation 2002;29:803-4). Two had re-
ceived haloperidol, while another received prochlorperazine and
droperidol. All three responded to discontinuing offending medi-
cations and supportive care. There were no deaths. The recogni-
tion of NMS in the post-transplantation setting is confounded by
multiple etiologies for fever and delirium in these patients. The
pathology of the disorder is felt to relate to dopamine blockade.
Initial treatments involve stopping inciting medications and sup-
portive care. Pharmacological interventions such as bromocriptine,
dantrolene sodium, and benzodiazepines should be used to shorten
duration of symptoms and improve survival.
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TACROLIMUS CONVERSION FROM INTRAVENOUS (I.V.) TO ORAL (P.O.)
IN ALLOGENEIC STEM CELL TRANSPLANTATION
Zimmerman, R.L., Petersen, K.A., Hardiman, P.S., Davis, T.L.,
Lynch, J.C., Devetten, M.P. University of Nebraska Medical Center,
Omaha, NE
Tacrolimus (FK506) is commonly used in allogeneic stem cell
transplantation (SCT) to prevent rejection and graft-versus-host
disease. Dosing recommendations are mostly based on studies
performed in solid-organ transplant recipients. The package insert
recommends a conversion rate of 1:4 when changing from the
intravenous to the oral formulation. We retrospectively reviewed
tacrolimus levels and toxicity in 32 patients who underwent allo-
geneic SCT between July 2001 and June 2003 using the package
insert recommended conversion rate. All patients started tacroli-
mus on day -1 at a dose of 0.03 mg/kg actual body weight by
continuous IV infusion. Levels were drawn peripherally on day1,
3, 5 and then biweekly. Target range for tacrolimus levels was
8-12 ng/mL. Conversion from IV to PO at a conversion rate of 1:4
occurred when patients could tolerate P.O. medication. Thirty-
two patients underwent alloSCT for a variety of hematologic
malignancies. Median age at the time of transplant was 43 year
(range 19-58), 78% underwent a MRD donor SCT, 3% a 5/6
MRD SCT, and 19% a MUD SCT, conditioning was Cy/TBI
(89%) or Bu/Cy2 (11%). Ninety-three percent of patients with
available data required at least one IV dose reduction, the median
day of IV to PO conversion was11 (range7-25). The median
Table. BAL Fluid: Mean Values Pre- and Post-Etanercept Therapy
n
TNF
(pg/mL)
TNFR1
(ng/mL)
sCD-14
(ng/mL)
LBP
(ng/mL)
MCP-1
(ng/mL)
Control-A 3 5.2 (0-16) .02 (.02-.03) 0 (0) 0 (0) 0.04 (.015-0.07)
Control-B 10 5.4 (0-23) .11 (.02-.37) 1.9 (0-8.8) 0 (0) 0.28 (0.02-1.0)
IPS pre-Tx 7 93 (0-500) .86 (.08-1.5)* 82.6 (0-250)* 331 (0-1000)* 20 (0.6-73.9)
IPS post-Tx 5 16 (10-23) .18 (.1-0.36)† 3.0 (0-6.2) 0 (0) 0.07 (.05-0.1)†
Controls were (A) a group of healthy volunteers or (B) transplant patients without IPS.
*P .05, IPS pre-tx versus Control-B, †P .05, IPS post-tx versus IPS pre-therapy.
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